Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00358943 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Study sites: 318 to 317
    • Publications: details revised at 8 of 8 entries
    • Eligibility criteria expanded, about 5 words
  2. Minor Study sites revised (318)v40
  3. Minor Study sites: 319 to 318v39
  4. Minor Study sites: 318 to 319v38
  5. Minor Study sites: 315 to 318v37
Show 35 earlier versionsHide 35 earlier versions
  1. Minor Study sites revised (315)v36
  2. Minor Study sites: 299 to 315v35
  3. Minor Study sites: 314 to 299
    • Start date: Apr 1991 to Apr 1, 1991
    v34
  4. Minor Site details revised at 1 of 314 sitesv33
  5. Minor Site details revised at 1 of 314 sitesv32
  6. Minor Study sites revised (314)v31
  7. Minor Study sites revised (314)v30
  8. Minor Study sites: 311 to 314v29
  9. Minor Study sites: 310 to 311v28
  10. Minor Site details revised at 2 of 310 sitesv27
  11. Minor Study sites: 308 to 310v26
  12. Minor Study sites: 221 to 308v25
  13. Notable Primary endpoints: 1 to 2
    • Eligibility criteria expanded, about 38 words
    • Study title expanded, about 4 words
    v24
  14. Notable Primary and study completion dates: Jan 31, 2030 to Jan 31, 2034
    • Study sites: 63 to 221
    v23
  15. Minor Publications: 6 to 8v22
  16. Minor Primary and study completion dates: Jan 2030 to Jan 31, 2030v21
  17. Minor Study sites: 1 to 63v20
  18. Minor 2 versions Re-verified since Aug 26, 2014, no change to tracked fieldsv18-v19
  19. Minor Study description shortened, about 47 wordsv17
  20. Minor Re-verified, no change to tracked fieldsv16
  21. Minor Enrollment target: 12000
    • Primary and study completion dates: Jan 2030
    v15
  22. Minor Study description shortened, about 1 wordv14
  23. Minor 4 versions Re-verified since Jul 30, 2009, no change to tracked fieldsv10-v13
  24. Minor Enrollment target: 99999 to not statedv9
  25. Minor Enrollment target: 99999v8
  26. Minor Re-verified, no change to tracked fieldsv7
  27. Minor Study Status, Study Design, Eligibilityv6
  28. Minor Eligibility criteria expanded, about 1 word
    • Study description expanded, about 1 word
    • Study title expanded, about 2 words
    v5
  29. Minor Start date: Nov 2001 to Apr 1991v4
  30. Minor Study description revisedv3
  31. Minor Study description shortened, about 290 words
    • Study site revised
    v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
284 trials monitored
See 12 trials at risk
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Registry are: * To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention. * To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care. * To characterize the Gaucher disease population. * To evaluate the long-term effectiveness of imiglucerase and of eliglustat. Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.
Trial Details
NCT Number NCT00358943
Lead Sponsor Genzyme, a Sanofi Company
Conditions
(from sponsor)
Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Related terms Gaucher Disease
Enrollment 12,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov